Multisite Research Ethics Review: Problems and Potential Solutions by Ferguson, Aidan & Master, Zubin
A Ferguson, Z Master BioéthiqueOnline 2016, 5/7
(http://bioethiqueonline.ca/5/7)
Multisite Research Ethics Review: Problems and Potential
Solutions
ARTICLE (RÉVISION PAR LES PAIRS / PEER-REVIEWED)
Aidan Ferguson1, Zubin Master2
Reçu/Received: 28 Aug 2015 Publié/Published: 31 Mar 2016
Éditeurs/Editors: Charles Dupras, Vanessa Chenel & Hadi Karshoho
Évaluateurs externes/Peer-Reviewers: Renata Axler & Anonymous
2016 A Ferguson, Z Master, Creative Commons Attribution 4.0 International License
Résumé Abstract
Les essais cliniques multicentriques à grande échelle ont
augmenté en fréquence. À l’heure actuelle, un projet de
recherche réalisé dans plusieurs institutions nécessite une
évaluation éthique pour chaque établissement. Bien que
l’évaluation (institutionnelle) locale peut être nécessaire
dans certains cas, les évaluations répétitives peuvent
nécessiter des changements inutiles et ne servent pas à
protéger davantage les participants. Il a été démontré que
le fait d’avoir plusieurs évaluations éthiques d’une seule
étude retarde la recherche et exige, dans certains cas, des
ressources importantes afin de satisfaire aux demandes
des différents comités d’éthique. Cette revue de la
littérature aborde les questions conceptuelles et présente
les recherches empiriques entourant l’évaluation éthique
multicentrique de différentes juridictions. Elle aborde
également les méthodes alternatives pour rationaliser le
processus d’évaluation éthique, y compris l’évaluation
réciproque et l’évaluation centralisée, ainsi qu'une
proposition de modification du processus d’évaluation
centralisé.
Large scale, multisite clinical research trials have been
increasing in frequency. As it stands currently, a research
project performed at multiple institutions requires ethics
review at each institution. While local (institutional) review
may be necessary in some instances, repetitive reviews
may require unnecessary changes and not serve to further
protect participants. Multiple ethics reviews of a single
study have been shown to delay research and require, in
some cases, significant resources in order to fulfill the
requests of individual ethics boards. This literature review
discusses the conceptual issues and outlines empirical
research surrounding multisite ethics review from different
jurisdictions, as well as alternative methods to streamline
the ethics review process including reciprocal review,
centralized review, and a proposed modification to the
centralized review process.
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Introduction 
In many countries, ethics review of research involving humans is performed locally by ethics boards
within institutions (e.g., hospitals, research centres, universities and colleges). Local review is
considered important because institutional boards are knowledgeable about the type of research
being conducted at their institution and the community’s traditions, education, risk factors, and
prevalence of certain health conditions [1,2]. Because of the close nature of the relationship between
institutions and their population, local review can also serve to enhance trust in researchers and the
institution. As more research involves large multicentre collaborations spanning states and countries,
especially in the context of public health research, ethics review has become increasingly complex
because individual ethics boards are required to independently review the same research protocol
performed at their institution. Several studies have shown that local ethics review of multi-institutional
or multisite research causes delays in the execution of research [3-8], drives-up research and
administrative costs [7-9], decreases participant enrolment [10], delays or deters the recruitment of
researchers and trainees on projects [11-12], and requires unnecessary changes including playing on
the wording of consent documents making them longer and more difficult to understand and requiring
minor word changes or formatting in specific documents none of which seem to further protect
participants [13-14]. Several conceptual and empirical studies have begun to surface and strategies to
streamline multisite review have been developed and are being implemented [13,15]. 
In this paper, we review the academic literature, with a focus on the United States and Canada,
regarding the ethical and practical considerations of multisite ethics review and discuss the
implementation of alternative review processes: reciprocal and centralized review. We report that
processes to consolidate review have several advantages while recognizing that in some cases,
individual review is still necessary. We conclude that both reciprocal and centralized review processes
have advantages and disadvantages for different reasons and that further research measuring the
effectiveness of multisite review is needed. With more knowledge on the efficacy of multisite ethics
review processes, government and non-government organizations can give more explicit directions on
how individual research ethics boards can participate in multisite processes.
The Status Quo: Research Ethics Review by Local Boards
The ethical review of publicly funded research involving humans is performed within nations, usually
through a mixture of federal and state/provincial policies. In both the U.S. and Canada, ethical review
of research is governed federally. In the U.S., ethics review of human research is governed through
federal regulations known as the Common Rule, which list provisions for board membership, informed
consent, and compliance by participating institutions [16]. Research ethics in Canada is governed by
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federal guidelines from the three federal funding agencies: Natural Sciences and Engineering
Research Council of Canada, Social Sciences and Humanities Research Council, and the Canadian
Institutes of Health Research in a policy known as the Tri-Council Policy Statement: Ethical Conduct
of Research Involving Humans, 2nd edition (TCPS2) [17]. In these countries and others, ethics review
is performed by local boards or committees: Institutional Review Boards (IRBs) in the U.S., Research
Ethics Boards (REBs) in Canada, and Research Ethics Committees (RECs) in the United Kingdom,
for instance. The main purpose of ethics review is to ensure that research is performed according to
certain ethical norms and standards in order to protect research participants [4-5,18]. While a
thorough review of the norms and practices governing research ethics is beyond the scope of this
paper, ethics boards generally assess several scientific and ethical aspects of research including
scientific value and validity, subject recruitment, risk-benefit analysis, informed consent, participant
withdrawal, privacy, adverse events monitoring and reporting, reporting of results and/or incidental
findings to participants, management of conflicts of interest, and adherence to international, federal
and state/provincial policies [19-22]. Ethics boards review a range of research including drug trials,
psychiatric studies, social science and psychology research, drug-based research, and surgical
studies among others [23-24]. Depending on the magnitude and type of research conducted within the
organization, institutions may have a general ethics board that reviews all research involving humans
or may have specialized boards that focus on particular areas of research (e.g., behavioural versus
clinical research).
Multisite research has become an increasingly common way to conduct research, as seen by an 8 to
9-fold increase between 1985 and 1999 in large cohort epidemiology studies [25]. Multisite studies
tend to recruit large numbers of heterogeneous or specific populations from different geographical
areas [2,6,8,10,13,26-28]. In particular, phase 3 and 4 clinical trials may require the recruitment of
hundreds of participants and often cover a large geographic area to increase generalizability. Such
studies require the concerted effort of many investigators at multiple institutions to recruit participants,
administer procedures, and collect data.
Several studies have examined the conduct of ethics review at multiple institutions using a range of
methods, including the review of ethics boards’ outcomes and perceptions of board members
[1,6,11,29-30] and researchers [4,31], examination of documents/records [32], and descriptive
review/analysis of individual board review and approval processes [12,33]. These studies have
outlined a range of issues in local ethics review of multisite research including variation in informed
consent [5-6,12,26], risk-benefit analysis [5,8,30,32,34], differences in board members’ understanding
of legislative and regulatory requirements [3,12,34], difficulty or confusion regarding privacy
compliance [4,26,32], differences in when to exempt research [5,13,32], delays in the commencement
and/or dissemination of research [1,3-6,8], and delays in the recruitment of participants [10].
Researchers also report frustration with many aspects of multisite ethics review, including delays, the
increased time, effort and cost to address changes, lack of cooperation between ethics boards, and
the lack of standardization in ethics review [4,31,35]. Unfortunately, the research community is
experiencing major issues with the way ethics boards respond to multisite research protocols that may
negatively impact researchers, potential and current research participants, and the public [2,8,36-38].
We need to be mindful, however, that inconsistencies in research ethics review across local boards
does not always imply a reduction in the quality of review. In some cases, repetition in review might
lead to greater scrutiny of the protocol and increase the quality of reviews. At the same time,
inconsistencies in ethics review can be administratively burdensome, not only for the ethics boards,
but also for researchers and it could lead to potential harms to research participants.
Inconsistencies in Ethics Review and Potential Harms to Participants
While inconsistencies in multisite review by local boards may not continually undermine the
thoroughness or quality of reviews, in some instances it could undercut certain protections offered to
participants. This can be seen with boards having varying expectations of the language used in
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informed consent documents, and how boards consider issues of risk, privacy, and equitable
participant selection.
Due to the emphasis that ethics board members place on informed consent, it is not surprising that
there are significant variations among them on this issue. For example, in the U.S., IRB-approved
protocols may include variation in consent requirements, and requested changes have been shown to
reduce the understanding of informed consent documents [39]. Silverman and colleagues [40]
analyzed informed consent documents of 16 IRBs participating in a multicentre trial and found that
IRBs varied in their requirements regarding the description of risks, benefits, alternate treatment
options, maintaining confidentiality, and informing patients that they are participating in research and
their participation is voluntary. Interestingly, 6 of 16 consent forms approved by IRBs failed to contain
any of the above elements and 9 provided incomplete information to participants about the
alternatives to participation. Another study showed that local review boards of 25 different sites made
a median of 46.5 changes to the consent form causing errors in two thirds of the forms and creating
forms that were longer and more difficult to read [2]. 
Beyond the variations in informed consent described above, equitable participant selection, protection
of vulnerable populations, and privacy and confidentiality measures may also change from one ethics
board to another. One study found that IRBs failed to adequately compare risks and benefits 21% of
the time, equitable subject selection 60% of the time, and privacy and confidentiality 12% of the
time [23]. Some ethics boards might approve a study as minimal risk with waiver of consent while
others outright rejected the application, requiring more information [12]. In one instance, an IRB
requested that copies of consent forms be kept in an administrative office of the participants’
employer, instead of the researcher’s office, which may have impinged on participant privacy and
negatively affected their employment [12].
Multiple studies point out that variation in research protocol, informed consent, administration, privacy
protections, and determining appropriate levels of risk can create, at a minimum, uneven human
protections that undermine the Common Rule [5,8-9,25,41-44]. Researchers warn that when the
“public hears about problems,” people could determine that “research might be unsafe and existing
protections ineffective,” thereby reducing the public’s trust and participation in research [41].
Despite the aforementioned studies showing variation among research ethics review, there are cases
where independent board reviews are necessary. For example, medical research conducted in rural
towns or communities may have participant populations with a reading level lower than the national
standard of about a grade 8 level. Here, an ethics board may require that informed consent be
brought down to a reading level suitable for the community to be best informed about a study prior to
their enrollment. There might also be cases where a large, culturally unique population resides and
has different values and views on informed consent. This is well recognized of many aboriginal
communities where there may be a different approach to performing research and obtaining consent.
Canada has drafted specific provisions, initially as separate guidelines and now part of the TCPS2, for
research involving aboriginal peoples [17]. Along with cases where local ethics review is required, it is
important to recognize that inconsistencies in the review of research protocols by local boards does
not necessarily equate, in all cases, with direct or indirect harm to participants.
Delays in Conducting and Disseminating Research During Local Ethics
Review of Multisite Studies
In addition to inconsistent reviews, another major concern reported in the academic literature
regarding multisite ethics review are delays in conducting and disseminating research due to
additional requests by boards for minor and likely unnecessary changes [14,32,35]. Several studies
show that submission-to-approval times range from as few as 5 days and up to 252 days [14,32].
Sarson-Lawrence [14] noted that 30% of changes requested by local boards were nothing more than
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“minor errors” such as word changes. In one example, researchers submitted 105,888 pages of
application materials to 125 ethics boards with an estimated cost of $10,286.83 for paper,
photocopying and postage for a single study, demonstrating staggering administrative costs [8]. Not
surprisingly, researchers involved in multisite studies report the process frustrating and unnecessarily
burdensome [15,31]. Delays in ethics board decisions may postpone recruitment [45] and will likely
lead to concomitant delays in the public reporting of research, ultimately postponing the transition of
medicines and diagnostics to the marketplace [36].
While regulations, guidelines, and accreditation offer guidance in research ethics review, they are not
overly prescriptive regarding consensus in the interpretation of research ethics practices. As
differences in individual board members’ interpretation of specific research protections exist, the
variation seen internally among board members and between different boards seems inescapable. To
reduce variation, several alternate models to ethics review of multisite research have been proposed
and implemented. In the examples below, we illustrate two common features that aim to reduce the
variation in the interpretation and implementation of research ethics review practices. The first aims to
reduce the number of separate reviews and the second involves agreeing on common practices and
procedures.
Alternate Models of Ethics Review of Multisite Studies
While local review has several advantages (e.g., knowing the study population), in some cases, it is
unclear whether local review is the most effective method for large, multicentre trials. Alternate
methods of multisite review might offer an opportunity to save time, energy, and resources, as well as
increase participant protections. To circumvent the issues outlined above, two common alternative
models for multicentre research ethics review have been suggested and implemented: reciprocal
review and centralized review (see Table 1). 
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Table 1: Institutions Implementing Reciprocal and Centralized Review Processes
Example Description Reference
Reciprocal Review
Harvard Catalyst 
Institutions
Consists of 9 institutions in the Boston area engaged in a reciprocal common IRB 
reliance agreement allowing a participating site to agree to use one IRB’s review for 
new submissions or amendments to the protocol for all participating institutions on a 
case-by-case basis. Winkler, Witte, & Bierer [47] noted that the Harvard Catalyst 
system of reciprocal review may reduce burden and inconsistencies inherent to single 
site review which may result in increased cooperation, trust and communication among
institutions. Located in the U.S. with multi-clinical focus. https://catalyst.harvard.edu/
46,47
Cancer Trials Australia Studied the use of a model of mutual acceptance where several National Health and 
Medical Research Councils agreed to accept the reviews of a primary Human 
Research Ethics Committee. Concluded that this model resulted in a 27% reduction in 
approval time and stakeholders professed a high level of approval in the system, 
although each site needed to complete a separate legal review following the ethical 
review by the primary ethics committee, which could delay the commencement of 
research. Cancer Trials Australia is a clinical trial network for oncology trials of single 
and multisite research projects that currently has 19 member institutions. Located in 
Australia, with a focus on cancer research. https://www.cancertrialsaustralia.com/
48
Centralized Review
Ontario Cancer 
Research Ethics 
Board (OCREB)
In 2003-2004, OCREB began reviewing multicentre oncology trials in Ontario and 
currently serves as the board of record for 26 of 27 hospital centres. The board is 
composed of medical/scientific experts, ethicists, researchers, healthcare providers, 
legal experts and community members. In a 2014 annual report, it was noted that the 
board reviewed approximately 70 new studies a year with an average approval taking 
only 56 days. The study also noted that 94% and 77% of stakeholders rated the review
services by this board as good or excellent, respectively. Located in Ontario, Canada, 
with a focus on cancer research. http://oicr.on.ca/oicr-programs-and-platforms/ontario-
cancer-research-ethics-board
49-51
National Cancer 
Institute Central IRB
This central IRB has 265 adult and 128 pediatric institutions that participate in a 
centralized review process where one review is completed by a central IRB for each 
proposal, as well as a facilitated review by the independent IRBs to address local 
issues. The central board is composed of scientific and non-scientific oncology 
experts, such as nurses, providers, patient representatives and statisticians. A study 
found the benefits of this review process to be more predictable, faster and cost-
effective on the initial review, but the savings accrued did not exceed the cost of 
running the centralized IRB ($55,000 a month). Located in the U.S, with a focus on 
cancer research. https://ncicirb.org/cirb/default.action
50,52
Multi-Centre Research
Ethics Committee 
(MREC)
Until 2004, some research institutions in the United Kingdom used a national review 
board, made up of several regional multi-centre research ethics committees, known as
the MREC. After review by the MREC, the same study protocol would be reviewed by 
the local REC in an attempt to expedite the review process for multicenter research. 
Unfortunately, the consolidated review process was met with considerable criticism 
from the research community who felt that centralization increased rather than 
decreased the inefficiencies in the review process. Located in the United Kingdom.
51
University of 
Alberta/Capital Health 
Region/Caritas 
Hospitals Group
The Health Research Ethics Board is contractually the review board of record for 
clinical research conducted within the University of Alberta, Capital Health Region and 
Caritas Hospitals Group. Located in the province of Alberta, Canada.
51
McGill University’s 
Faculty of Medicine
McGill University’s Faculty of Medicine uses affiliation agreements with other 
participating institutions to facilitate a centralized review process within their 
participating sites. It was noted that these partnerships provided not only enhanced 
protections for participants, but work on the basis of trust between the institutions, 
negating the need for local review of proposals. This review board reviews clinical 
research. Located in the province of Quebec, Canada.
51
Harmonization of 
Multi-centre Ethical 
Review
In 2006, the Australian Health Ministry Advisory Council sought to implement a 
national system of centralized review entitled Harmonization of Multi-centre Ethical 
Review (HoMER), although local approval must still be gained following the centralized
review approval. 
53
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Reciprocal Review
Reciprocal review entails an arrangement between two or more ethics boards at different institutions
who agree to accept the ethics review conducted by another board [15]. Establishing a reciprocal
arrangement usually requires participating boards to develop a trusting relationship, a common means
of assessing protocols, a common set of forms and templates provided to researchers, and may
include having similar standard operating procedures. To operationalize reciprocal review, individual
ethics boards need to reach a common agreement on concerns about liability, timeliness of reporting
adverse events, approaches to review, and the considerations of taking corrective actions on
protocols when in violation of research ethics policy. These challenges are not to be taken lightly as
the process of setting up reciprocal arrangements takes a significant amount of time of the boards’
chairs, members and administrative staff, and other university staff (e.g., Vice-President Research,
legal services). The process of establishing reciprocal agreements is likely to be a costly endeavor
due to the initial time and resource investment, which might deter boards from initiating reciprocal
agreements as they simply do not have the time and resources. 
Several institutions have implemented reciprocal review processes with some indication of success
(Table 1). Cancer Trials Australia resulted in reduced review time, but the arrangement required an
initial investment by institutions, researchers and review boards [48]. Some boards may be reluctant
to defer their review power to another authority, and may experience trepidation due to a
misunderstanding of the process. Reciprocal review can be a viable option for local boards to
consider, but additional research is needed regarding their establishment and efficiency.
Centralized Review
Centralized review is when several research institutions enter into an agreement to allow one board to
conduct ethics reviews on behalf of all the participating sites; the board reviewing the protocol
becomes an official board of record. Centralized review boards may consist of individuals with specific
expertise in a particular subject area, such as cancer research, and this may serve for a more
thorough ethics review, enhance participant protection, and better distribute workload
[10,15,18,28,51,54]. In some circumstances, centralized review does not completely eliminate
individual boards from conducting an administrative review to determine whether to accept the board
of record’s review.
Boards in many states/provinces and countries have in place, or are in the process of establishing,
centralized review systems (Table 1). Centralized review can reduce costs by ensuring less
duplication of paperwork, reduced variability, and fewer delays in participant enrolment and the
commencement of research [27], as well as ensure that unexpected and adverse events are quickly
identified and reported so corrective action can be taken [18]. Centralized review can reduce the
burden on investigators, increase consistency in the protection of research participants, and ensure
quick dissemination of any change in protocol to participating institutions [11,18,55-57]. One novel
suggestion from the U.S. is to conduct centralized review virtually; overseen by U.S. Office of Human
Research Protections, this would allow reviewers to remain at their institutions but provide
“unprecedented” expert review specific to the research at hand, as well as real time information
regarding adverse events and monitoring [43,58]. Other authors suggest something similar, using a
“web-based cooperative IRB review” that would enable reviewers from other geographic areas to
interact [59]. Another suggestion, by Mann and Shamoo [57], is the establishment of a system of
centralized regional ethics organizations that could promote the involvement of the research ethics
community as a way to improve oversight for industry sponsored research.
However, concerns have been raised about centralized review: 1) legal concerns of one board
accepting the review of another; 2) centralized boards might not understand the culture of
participating ethics boards/institutions and the needs of the local population; and 3) centralized boards
might not be able to communicate effectively with local investigators [15,29,48,55,58]. Autonomy and
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independence of boards continues to be touted as desirable in order to understand community-
specific needs resulting in a preference towards local control [1]. Due to uneasiness over accepting
another ethics boards’ decision, and confusion over how ethics and human protections issues are
handled through an outside board, researchers and research institutions have concerns that local
boards may not have the motivation and lack experience in participating in a centralized review
process [60]. In spite of these concerns, several organizations – including the U.S. Department of
Agriculture and the Department of Health and Human Services – have demonstrated support for using
a centralized approach [60]. Centralized review, while having some drawbacks, does seem to provide
a reduction in workload, faster review times, and better distribution of changes to the protocol.
While both reciprocal and centralized review has their place, in some cases, multisite review
mechanisms might be less appropriate and local review would be necessary. One example would be
the need for a catholic hospital to review all protocols to ensure that research on abortion or using
aborted fetuses would not be permitted. A second example that may limit multisite review
mechanisms from being established is based on differences in jurisdictional policies. For example,
privacy policies from different provinces in Canada may differ in the safeguards that need to be in
place. The heterogeneity in national and state/provincial policies might limit such multisite ethics
review processes from being practiced in geographically dispersed areas.
Current Guidance to Ethics Boards on Multisite Ethics Review
As research expands from single site into multisite research, governing bodies have had to address
the ethical conduct of research in these new settings. In Canada, the TCPS2 [17] now has a specific
chapter devoted to multi-jurisdictional research in an effort to ensure that the same ethical
considerations and procedures used in reviewing single site research are not overlooked in multisite
review. The TCPS2 places the responsibility of ensuring ethical conduct of research and the decision
of whether to use traditional or alternate review processes on institutional REBs, and offers little in
terms of guidance on how alternate review practices could be implemented [17]. The U.S. Department
of Health and Human Services regulations provide a statement allowing IRBs to enter into a “joint
review arrangement” [61]. Similarly, the Common Rule explains that multisite studies may benefit from
minimizing burden and increasing effectiveness, but provides little guidance on how to establish such
practices [62]. In 2011, the Department of Health and Human Services issued an advance notice of
proposed rulemaking (ANPRM) [61] soliciting comments for updating several regulations, including
the streamlining of IRB review for multiple sites through the designation of one IRB of record. The
ANPRM points out that the Common Rule requires researchers to obtain IRB approval, but does not
require that this approval come from each local board participating in the research project. 
In September 2015, a Notice of Proposed Rulemaking (NPRM) [63] was released, following the
ANPRM in 2011, for comment on proposed changes to the Common Rule, including a
recommendation for a centralized review process to be used in multisite research. Proposed changes
included a mandate for institutions to use an IRB of record for multisite research instead of reliance on
individual review by local review boards. The NPRM also recommends that the review board of record
be given the ability to enforce compliance on unaffiliated/non-conforming review boards and be held
liable for flawed review instead of local review boards. The expectation is that the proposed changes
will dispel unease with individual review boards ceding control to another board, promote collaboration
between review boards, and remove arduous review processes [63]. However, the proposed changes
do not address how to hold unaffiliated review boards accountable nor how individual review boards
can go about selecting a review board of record considering that the latter will be responsible for any
liability. Because these recommendations are not fully explained, it may be difficult to convince
individual review boards to use a centralized review process based on these proposed changes.
While it appears that many major national policies are starting to recognize the need for multisite
review through the introduction of some guidance in policy statements, review boards may continue to
be reluctant to institute alternate review strategies without increased support and guidance. 
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Limitations
While this literature review considers international studies of multisite research ethics review (though
primarily from the U.S. and Canada), it is important to note the context under which these studies
were conducted, such as jurisdiction of review, national, state/provincial policies, and the type of study
(behavioural vs. clinical). The literature review also focuses on publicly funded research using
academic review boards; privately/sponsored research and private boards may have different
experiences. 
Conclusion
Our analysis of the literature on multisite ethics review suggests that local review boards can offer
advantages of improved understanding of local community needs and traditions. This may, however,
result in inconsistency in review requiring unnecessary changes that can drive-up costs and delay
research. While alternate review processes may better control inconsistencies in the review process,
they will not necessarily lead to a better quality of review in all cases. Some local review boards have
shown resistance to reforming the review process for multisite studies, but this resistance may be due
to unsubstantiated perceptions of legal liability and accountability, and the desire to understand local
needs. Because adoption of multisite review practices take a substantial amount of time, energy,
knowledge and financial resources, local boards may be reluctant to begin changing practices.
Centralized and reciprocal review processes have several advantages. Centralized review boards
have been shown to better address ethics reviews in a specialized area of research, e.g., cancer
research, whereas boards engaged in reciprocal review may be more efficient at uniting individual
boards in a certain geographical area. One issue that might prevent reciprocal arrangements or
boards engaging in centralized review processes is that of trust. Having a committee of experts in
cancer research with ethics board members concentrating only in a specialized area may result in
enhancing trust in the centralized board and the review process. Similarly, boards in a certain
geographical area, which know their patient population, might also begin undertaking the development
of common forms and templates and gradually build trust in the process of developing a reciprocal
agreement. Both centralized and reciprocal review thus have their place in ensuring robust ethics
review while striving for greater efficiency in the process.
We propose a modification of centralized ethics review that aims to streamline the ethics review
process by having a single board of record, but by also having non-voting representatives of individual
boards. This might help address concerns of trust and ensure that due diligence by the central board
meets the standards of individual boards. Concerns can be voiced and brought up, but individual
board representatives cannot vote in order to ensure timely ethics review. Having a venue for local
boards to express concerns present in their local community is likely a feature they would deem
important and offer them the satisfaction that their voices can be heard. If representatives believe that
the reviews being conducted are not up to their standards, they can relay this back to their board
chairs and members and make a decision on whether to continue participating. By having a
representative on the central board, representatives can witness the integrity and quality of the review
process, communicate concerns, and relay issues back to their individual board. Individual
representatives may participate by attending meetings or attend meetings via video or teleconference
when their protocol is being reviewed. While this modification may reduce localized issues, one
limitation is that there can only be a limited number of individual board representatives who can
attend. The centralized board can develop procedures to have board representatives periodically
attend meetings, initially when the individual board joins the centralized process, and when there is a
particularly contentious or problematic research project being reviewed. A second limitation to this
process is that overall, the process may take slightly more time due to the need to call in individual
board representatives when protocols are being reviewed and a greater degree of organization would
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be needed by the centralized board of record to manage protocols by different boards and to
consolidate review.
Although greater guidance on multisite ethics review is given, most notably in the NPRM in the U.S.,
there remains little detailed direction on several of the salient issues that individual boards need to
address prior to any reform, e.g., time, financial resources, trust, and perceptions of accountability and
liability. We argue that greater policy direction is needed as independent boards are likely aware of
these issues, but may not have the means and knowledge to undertake reforms. Collaboration
between national and local levels in policy/regulation development might provide more ease with
implementation, while national agencies overseeing ethics review, or other non-government bodies or
groups interested in research ethics, could make efforts to educate Chairs, leaders and members of
independent boards. This could be done through education efforts such as specialized workshops or
conferences where legal, policy and logistic issues are discussed in greater detail to help independent
boards gain the necessary knowledge to begin the process of joining or creating a multisite ethics
review process. While this may not circumvent resource issues, universities, colleges and
hospitals/research centres must invest further in their independent boards in order to actualize a
process of multisite ethics review.
As a more reciprocal and centralized review strategies are implemented, further research is also
needed on these initiatives, not only in terms of how efficiently multisite review is performed, but also
the steps and hurdles that local boards encounter during the development of uniform review policies
and practices. While there are certainly instances where local review may be necessary, in many
cases stakeholders in research practice and governance may benefit from more streamlined and
collaborative processes.
References
1. Klitzman R. The myth of community differences as the cause of variations among IRBs. AJOB 
Primary Research 2011; 2(2): 24-33.
2. Burman W, Breese P, Weis S., et al. The effects of local review on informed consent 
documents from a multicenter clinical trials consortium. Controlled Clinical Trials 2003; 24(3): 
245-255.
3. Dyrbye LN, Thomas MR, Mechaber AJ, et al. Medical education research and IRB review: an 
analysis and comparison of the IRB review process at six institutions. Academic Medicine 
2007; 82(7): 654-660.
4. Ezzat H, Ross S, von Dadelszen P, et al. Ethics review as a component of institutional 
approval for a multicentre continuous quality improvement project: the investigator’s 
perspective. BMC Health Services Research 2010; 10(1): 223.
5. Larson E, Bratts T, Zwanziger J, et al. A survey of IRB process in 68 US hospitals. Journal of 
Nursing Scholarship 2004; 36(3): 260-264.
6. Driscoll A, Currey J, Worrall‐Carter L, Stewart S. Ethical dilemmas of a large national multi  ‐
centre study in Australia: time for some consistency. Journal of Clinical Nursing 2008; 17(16): 
2212-2220.
7. Salman RAS, Brock TM, Dennis MS, et al. Research governance impediments to clinical trials:
a retrospective survey. Journal of the Royal Society of Medicine 2007; 100(2): 101-104.
8. Gold JL, Dewa CS. Institutional review boards and multisite studies in health services 
research: is there a better way? Health Services Research 2005; 40(1): 291-308.
9. Willison DJ, Emerson C, Szala-Meneok, et al. Access to medical records for research 
purposes: varying perceptions across research ethics boards. Journal of Medical Ethics 2008; 
34(4): 308-314.
10. Peterson LA, Simpson K, SoRelle R, et al. How variability in the institution review board review
process affects minimal-risk multisite health services research. Annals of Internal Medicine 
2012; 156(10): 728-735.
ISSN 1923-2799 10 / 13
A Ferguson, Z Master BioéthiqueOnline 2016, 5/7
(http://bioethiqueonline.ca/5/7)
11. Mansbach J, Acholonu U, Clark S, et al. Variation in institutional review board responses to a 
standard, observational, pediatric research protocol. Academic Emergency Medicine 2007; 
14(4): 377-380.
12. Green LA, Lower JC, Kowalski CP, Wyszewianski L. Impact of institutional review board 
practice variation on observational health services research. Health Services Research 2006; 
41(1): 214-230.
13. Greene SM, Geiger AM. A review finds that multicenter studies face substantial challenges but
strategies exist to achieve Institutional Review Board approval. Journal of Clinical 
Epidemiology 2006; 59(8): 784-790.
14. Sarson‐Lawrence M, Alt C, Mok MT, et al. Trust and confidence: towards mutual acceptance 
of ethics committee approval of multicentre studies. Internal Medicine Journal 2004; 34(11): 
598-603.
15. Abbott J, Bergeron M, Hoddinott S, et al. Ethics review of research involving multiple setting 
and/or involving multiple REBs (previously multicentered ethics review): a discussion paper 
and recommendations. Subgroup on Procedural Issues for the TCPS (ProGroup): A Working 
Committee of the Interagency Advisory Panel on Research Ethics (PRE); 2008. 
16. U.S. Department of Health and Human Services. Code of Federal Regulations: Title 45 Public 
Welfare: Part 46 Protection Of Human Subjects (45 CFR 46); 2009.
17. Panel on Research Ethics. Tri-Council Policy Statement: Ethical Conduct for Research 
Involving Humans, second edition (TCPS2); 2014.
18. Emanuel EJ, Wood A, Fleischman A, et al. Oversight of human participants research: 
identifying problems to evaluate reform proposals. Annals of Internal Medicine 2004; 141(4): 
282-291.
19. Smith E, Master Z. Ethical practice of research involving humans. Reference Module in 
Biomedical Research 3rd Edition. Oxford: Elsevier; 2014 
20. Vick CC, Finan KR, Kiefe C, et al. Variation in Institutional Review processes for a multisite 
observational study. The American Journal of Surgery 2005; 190(5): 805-809.
21. Sieber JE. Ethical considerations in planning and conducting research on human subjects. 
Academic Medicine 1993; 68(9): S9-13.
22. Sullivan GM. Education research and human subject protection: crossing the IRB quagmire. 
Journal of Graduate Medical Education 2011; 3(1): 1-4.
23. Lidz CW, Appelbaum PS, Arnold R, et al. How closely do institutional review boards follow the 
Common Rule? Academic Medicine 2012; 87(7): 969-974.
24. Saleem T, Khalid U. Institutional review boards - a mixed blessing. International Archives of 
Medicine 2011, 4:19. 
25. McWilliams R, Hoover-Fong J, Hamosh A, et al. Problematic variation in local institutional 
review of a multicenter genetic epidemiology study. JAMA 2003; 290(3): 360-366.
26. Sherwood ML, Buchinsky FJ, Quigley MR, et al. Unique challenges of obtaining regulatory 
approval for a multicenter protocol to study the genetics of RRP and suggested remedies. 
Otolaryngology - Head and Neck Surgery 2006; 135(2): 189-196.
27. Hammatt ZH, Nishitani J, Heslin KC, et al. Partnering to harmonize IRBs for community-
engaged research to reduce health disparities. Journal of Health Care for the Poor and 
Underserved 2011; 22(4 Suppl): 8-15.
28. Wadman M. Proposed centralization of trial oversight stirs mixed reaction. Nature Medicine 
2011; 17(9): 1025.
29. Helfand BT, Mongiu AK, Roehrborn CG, et al. Variation in institutional review board responses
to a standard protocol for a multicenter randomized, controlled surgical trial. The Journal of 
Urology 2009; 181(6): 2674-2679.
30. Shah S, Whittle A, Wilfond B, et al. How do institutional review boards apply the federal risk 
and benefit standards for pediatric research? JAMA 2004; 291(4): 476-482.
31. Master Z, Ries NM, Caulfield T. Balancing efficiency and the protection of research 
participants: Canadian Allergy/Asthma Researchers’ perspectives on the ethics review of 
multi-site health research. Journal of Clinical Research Bioethics 2011; 2(5): 104e.
ISSN 1923-2799 11 / 13
A Ferguson, Z Master BioéthiqueOnline 2016, 5/7
(http://bioethiqueonline.ca/5/7)
32. Dziak K, Anderson R, Sevick MA, et al. Variations among Institutional Review Board reviews 
in a multisite health services research study. Health Services Research 2005; 40(1): 279-290.
33. Hirshon JM, Krugman SD, Witting MD, et al. Variability in Institutional Review Board 
Assessment of Minimal  ‐  risk Research. Academic Emergency Medicine 2002; 9(12): 1417-
1420.
34. Blustein J, Regenstein M, Siegel B, Billings J. Notes from the field: jumpstarting the IRB 
approval process in multicenter studies. Health Services Research 2007; 42(4): 1773-1782.
35. Abramovici, A, Salazar A, Edvalson, T, et al. Review of multicenter studies by multiple 
institutional review boards: characteristics and outcomes for perinatal studies implemented by 
a multicenter network. American Journal of Obstetrics 2015; 212(1): 110.e1-110.e6.
36. Millium J, Menikoff J. Streamlining ethical review. Annals of Internal Medicine 2010; 153(10): 
655-657.
37. Studdert DM, Vu TM, Fox SS, et al. Ethics review of multisite studies: the difficult case of 
community-based Indigenous health research. Medical Journal of Australia 2010; 192(5): 275-
280.
38. Legro RS. Barriers to conducting clinical research in reproductive medicine: United States of 
America. Fertility and Sterility 2011; 96(4): 817-819.
39. Candilis, PJ, Lidz CW, Arnold RM. (2006). The need to understand IRB deliberations. IRB: 
Ethics & Human Research 2006; 28(1): 1-5.
40. Silverman H, Hull SC, Sugarman J. Variability among institutional review boards’ decisions 
within the context of a multicenter trial. Critical Care Medicine 2001; 29(2): 235-241.
41. Abbott L, Grady C. A systematic review of the empirical literature evaluating IRBs: what we 
know and what we still need to learn. Journal of Empirical Research on Human Research 
Ethics 2011; 6(1): 3-19.
42. Boult M, Fitzpatrick K, Maddern G. A guide to multi  ‐  centre ethics for surgical research in 
Australia and New Zealand. ANZ Journal of Surgery 2011; 81(3): 132-136.
43. Salvulescu J. Harm, ethics committees and the gene therapy death. Journal of Medical Ethics 
2001; 27(3): 148-150.
44. McWilliams R, Hebden CW, Gilpin AMK. Concept paper: a virtual centralized IRB system. 
Accountability in Research 2006; 13(1): 25-45.
45. Finch SA, Barkin SL, Wasserman RC. Effects of local institutional review board review on 
participation in national practice-based research network studies. Archives of Pediatrics & 
Adolescent Medicine 2009; 163(12): 1130-1134.
46. Harvard Catalyst. Regulatory Foundations, Ethics and Law Program: Master Reciprocal 
Common IRB Reliance Agreement. (n.d.).
47. Winkler SJ, Witte E, Bierer BE. The Harvard catalyst common reciprocal IRB reliance 
agreement: an innovative approach to multisite IRB review and oversight. Clinical and 
Translational Science, 2015; 8(1): 57-66.
48. Rosenthal MA, Sarson-Lawrence M, Alt C, et al. Ethics committee reviews and mutual 
acceptance: a pilot study. Internal Medicine Journal 2005; 35(11): 650-654.
49. Ontario Cancer Research Ethics Board. Annual report 2013-2014; 2014. 
50. Saginur R, Dent SF, Schwartz L, et al. Ontario Cancer Research Ethics Board: lessons 
learned from developing a multicenter regional institutional review board. Journal of Clinical 
Oncology 2008; 26(9): 1479-1482.
51. Enzle ME, Schmaltz R. Ethics review of multi-centre clinical trials in Canada. Health Law 
Review 2005; 13(2-3): 51-7.
52. Wagner TH, Murray C, Goldberg J, et al. Costs and benefits of the national cancer institute 
central institutional review board. Journal of Clinical Oncology 2010; 28(4): 662-666.
53. Prosser B, Davey R, Gibson D. Progress in centralised ethics review processes: implications 
for multi-study health evaluations. Evaluation and Program Planning, 2015; 49: 117-123.
54. Fitzgerald MH, Phillips PA. Centralized and non-centralized ethics review: a five nation study. 
Accountability in Research 2006; 13(1): 47-74.
ISSN 1923-2799 12 / 13
A Ferguson, Z Master BioéthiqueOnline 2016, 5/7
(http://bioethiqueonline.ca/5/7)
55. Resnik DB. Centralized institutional review boards: Assessing the arguments and evidence. 
Journal of Clinical Research Best Practices 2012; 8(11): 1-13.
56. Ravina B, Deuel L, Siderowf A, Dorsey ER. Local IRB review of a multicenter trial: local costs 
without local context. Annals of Neurology 2010; 67(2): 258-260.
57. Mann H, Shamoo AE. Introduction to special issue of accountability in research on the review 
and approval of biomedical research proposals: a call for a centralized national human 
research protections system. Accountability in Research 2006; 13(1): 1-9.
58. Caulfield T, Ries N, Barr G. Variation in ethics review of multi-site research initiatives. 
Amsterdam Law Forum 2011; 3: 85-100.
59. Nowak KS, Bankert EA, Nelson RM. Reforming the oversight of multi-site clinical research: a 
review of two possible solutions. Accountability in Research, 2006; 13(1): 11-24.
60. Flynn KE, Hahn CL, Kramer JM, et al. Using central IRBs for multicenter clinical trials in the 
United States. PloS one 2013; 8(1): e54999. doi: 10.1371/journal.pone.0054999.
61. Department of Health and Human Services. Human Subjects Research Protections: 
Enhancing Protections for Research Subjects and Reducing Burden, Delay, and Ambiguity for 
Investigators. Federal Register 2011; 76 FR 44512: 44512-44531
62. Emanuel EJ, Menikoff J. Reforming the regulations governing research with human subjects. 
New England Journal of Medicine 2011; 365(12): 1145-1150.
63. Department of Health and Human Services. Notice of Proposed Rulemaking for Revisions of 
the Common Rule. Federal Register, 2015; 80 FR 53931: 53931-54061.
ISSN 1923-2799 13 / 13
